Free Trial

Gemini Therapeutics (GMTX) Competitors

Gemini Therapeutics logo
$89.94 +15.58 (+20.95%)
As of 10/17/2025

GMTX vs. RDY, VTRS, ROIV, BBIO, QGEN, MRNA, ELAN, VRNA, RVMD, and ABVX

Should you be buying Gemini Therapeutics stock or one of its competitors? The main competitors of Gemini Therapeutics include Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Roivant Sciences (ROIV), BridgeBio Pharma (BBIO), Qiagen (QGEN), Moderna (MRNA), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), and Abivax (ABVX). These companies are all part of the "pharmaceutical products" industry.

Gemini Therapeutics vs. Its Competitors

Gemini Therapeutics (NASDAQ:GMTX) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Dr. Reddy's Laboratories has a consensus price target of $16.95, suggesting a potential upside of 17.42%. Given Dr. Reddy's Laboratories' stronger consensus rating and higher probable upside, analysts plainly believe Dr. Reddy's Laboratories is more favorable than Gemini Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gemini Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Dr. Reddy's Laboratories
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.83

Gemini Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500.

In the previous week, Dr. Reddy's Laboratories had 4 more articles in the media than Gemini Therapeutics. MarketBeat recorded 4 mentions for Dr. Reddy's Laboratories and 0 mentions for Gemini Therapeutics. Dr. Reddy's Laboratories' average media sentiment score of 1.28 beat Gemini Therapeutics' score of 0.67 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media.

Company Overall Sentiment
Gemini Therapeutics Positive
Dr. Reddy's Laboratories Positive

Dr. Reddy's Laboratories has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gemini TherapeuticsN/AN/A-$71.87M-$1.00-89.94
Dr. Reddy's Laboratories$334.26B0.04$663M$0.6621.87

Dr. Reddy's Laboratories has a net margin of 16.99% compared to Gemini Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 17.25% beat Gemini Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Gemini TherapeuticsN/A -38.78% -35.88%
Dr. Reddy's Laboratories 16.99%17.25%11.63%

75.4% of Gemini Therapeutics shares are held by institutional investors. Comparatively, 3.8% of Dr. Reddy's Laboratories shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Dr. Reddy's Laboratories beats Gemini Therapeutics on 14 of the 16 factors compared between the two stocks.

Get Gemini Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GMTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GMTX vs. The Competition

MetricGemini TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$3.90B$1.03B$6.09B$10.49B
Dividend YieldN/A4.84%5.73%4.80%
P/E Ratio-89.941.3285.3827.13
Price / SalesN/A147.79519.70179.85
Price / CashN/A17.6337.2361.22
Price / Book31.128.0712.236.52
Net Income-$71.87M-$7.36M$3.33B$276.93M
7 Day Performance28.67%-1.70%1.18%1.94%
1 Month Performance47.36%27.11%6.15%2.19%
1 Year Performance78.13%-12.95%60.00%35.00%

Gemini Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GMTX
Gemini Therapeutics
N/A$89.94
+21.0%
N/A+54.9%$3.90BN/A-89.9430Gap Up
High Trading Volume
RDY
Dr. Reddy's Laboratories
3.0633 of 5 stars
$13.95
-2.9%
$16.95
+21.5%
-9.6%$11.64B$3.81B21.1327,811Positive News
VTRS
Viatris
3.0514 of 5 stars
$9.93
+0.7%
$10.40
+4.7%
-13.2%$11.58B$14.74B-3.4232,000News Coverage
Analyst Forecast
ROIV
Roivant Sciences
2.9452 of 5 stars
$16.40
+1.2%
$19.94
+21.6%
+44.9%$11.20B$29.05M-23.43860Insider Trade
BBIO
BridgeBio Pharma
4.4915 of 5 stars
$56.50
+1.0%
$63.94
+13.2%
+109.7%$10.80B$221.90M-13.81400Positive News
Analyst Revision
QGEN
Qiagen
4.1173 of 5 stars
$47.49
+0.6%
$49.40
+4.0%
+16.3%$10.56B$1.98B28.065,765News Coverage
Positive News
MRNA
Moderna
4.2557 of 5 stars
$26.25
-1.8%
$41.81
+59.3%
-52.6%$10.25B$3.24B-3.495,800Trending News
Options Volume
Analyst Revision
Gap Down
ELAN
Elanco Animal Health
2.586 of 5 stars
$20.25
+1.0%
$19.14
-5.4%
+66.9%$10.06B$4.44B23.549,000Analyst Revision
VRNA
Verona Pharma PLC American Depositary Share
1.5418 of 5 stars
$106.91
flat
$109.00
+2.0%
N/A$9.21B$42.28M-107.9930Positive News
RVMD
Revolution Medicines
4.3971 of 5 stars
$47.50
-2.6%
$74.64
+57.1%
+8.2%$8.88B$11.58M-10.56250News Coverage
Analyst Forecast
Insider Trade
ABVX
Abivax
3.5024 of 5 stars
$97.82
+2.3%
$114.25
+16.8%
+795.9%$7.61BN/A0.0061Short Interest ↓

Related Companies and Tools


This page (NASDAQ:GMTX) was last updated on 10/18/2025 by MarketBeat.com Staff
From Our Partners